Interferon-lambda Genotype and Low Serum Low-Density Lipoprotein Cholesterol Levels in Patients with Chronic Hepatitis C Infection

Institute for Genome Sciences and Policy, Durham, NC 27708, USA.
Hepatology (Impact Factor: 11.19). 06/2010; 51(6):1904-11. DOI: 10.1002/hep.23592
Source: PubMed

ABSTRACT Recently, genetic polymorphisms occurring in the interferon (IFN)-lambda gene region were associated with response to IFN-based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with decreased serum cholesterol and high cholesterol has been associated with increased likelihood to respond to IFN. We sought to determine if the IFN-lambda gene variant was also associated with serum lipid levels in chronic hepatitis C patients. We compared genotypes of the rs12979860 polymorphism, located proximal to the IL28 gene, with serum lipid and apolipoprotein levels in 746 subjects with chronic hepatitis C virus infection, not currently undergoing treatment, using multivariable analysis of variance. Levels of total cholesterol (P = 6.0 x 10(-4)), apolipoprotein B (P = 1.3 x 10(-6)) and low-density lipoprotein (LDL) cholesterol (P = 8.9 x 10(-10)) were significantly higher in subjects carrying the rs12979860 CC responder genotype compared with those with the CT or TT genotype. Levels of triglycerides (P = 0.03), apolipoprotein A-I (P = 0.06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype. CONCLUSION: Our results suggest that low levels of LDL cholesterol in chronic hepatitis C patients may be a marker of host endogenous IFN response to hepatitis C and that subjects with the rs12979860 CC responder genotype may have a lower endogenous IFN response to the virus.


Available from: Josephine H Li, Apr 21, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & AimsPredictors of response to treatment with peginterferon plus ribavirin are well established. In these post-hoc analyses of the REALIZE study we sought to identify predictors of response for telaprevir-based triple therapyMethods Patients from the REALIZE study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response, and baseline laboratory assessments) were included in the post-hoc analyses (n = 465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes.ResultsSustained viral response (SVR) rates were 86% in prior relapsers, 63% in prior partial responders, and 32% in prior null responders. In the final multivariate analysis, baseline factors predicting SVR were prior response to treatment (Odds ratio [OR] = 2.80; 95% confidence interval [CI], 2.13–3.69), low density lipoprotein (LDL) (≥2.6 mmol/L) (OR = 2.11; 95% CI, 1.52–2.93), HCV genotype (OR = 0.58; 95% CI, 0.36–0.93), and maximum alanine amino transferase and aspartate amino transferase (OR = 0.62; 95% CI, 0.40–0.97).Conclusions Prior response to peginterferon plus ribavirin treatment and LDL levels are the main independent predictive markers of response with telaprevir-based triple therapy.This article is protected by copyright. All rights reserved.
    Liver international: official journal of the International Association for the Study of the Liver 10/2014; 35(2). DOI:10.1111/liv.12703 · 4.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background & AimsWhile genetic polymorphisms upstream of the Interleukin-28B (IL28B) gene are associated with necroinflammatory activity grade in chronic hepatitis C genotype 1 (HCV-1) infection, any association with fibrosis is less definitive. We analyzed pre-treatment liver biopsies in a cohort of treatment-naïve patients with HCV-1 to evaluate associations between liver histology and the rs12979860 and rs8099917 IL28B single nucleotide polymorphisms (SNPs). Methods266 patients with HCV-1 infection and pre-treatment liver biopsy were tested for the rs12979860 and rs8099917 SNPs. Predictors of advanced fibrosis (METAVIR F3/4) and high activity grade (A2/3) were identified using multivariable logistic regression analysis. Results44 patients (16.5%) had advanced fibrosis and 141 patients (53.0%) high activity grade. Prevalence of rs12979860 IL28B genotype was: CC 45.7%, CT 42.7% and TT 11.6%. Prevalence of advanced fibrosis was lower in those with IL28B CC genotype compared to those without (11.0% vs 21.3%; P=0.03), with an increasing number of T alleles associated with a higher frequency of advanced fibrosis: CC 11.0%, CT 18.0%, TT 33.3% (P=0.01). Predictors of advanced fibrosis on multivariate analysis were platelet count (OR 0.98, 95% CI 0.97-0.99; P<0.0001), high activity grade (OR 5.68, 95% CI% 1.86-17.32; P=0.002), IL28B rs12979860 CC genotype (OR 0.36, 95% CI 0.14-0.93; P=0.03) and AST (OR 1.02, 95% CI 1.00-1.03; P=0.046). No association was found between rs8099917 IL28B genotype and liver histology. ConclusionsIL28B rs12979860 CC genotype appears to be independently associated with a lower prevalence of advanced fibrosis stage in HCV-1 infection. This association warrants further evaluation.
    Journal of Gastroenterology and Hepatology 02/2014; 29(7). DOI:10.1111/jgh.12544 · 3.63 Impact Factor
  • Hepatology 10/2014; 61(3). DOI:10.1002/hep.27581 · 11.19 Impact Factor